Exposure to CYP3A4-inducing and CYP3A4-non-inducing antiepileptic agents and the risk of fractures

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 6, 2011, Pages 619-625

  Schelleman, Hedi ^b   Pollard, John R ^a   Newcomb, Craig ^b   Markowitz, Clyde E ^a   Bilker, Warren B ^b   Leonard, Mary B ^b   Hennessy, Sean ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiepileptic; CYP3A4; Fractures

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; CYTOCHROME P450 3A4; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PIRACETAM; PRIMIDONE; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME INDUCTION; EPILEPSY; FEMALE; FRACTURE; FRAGILITY FRACTURE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANTICONVULSANTS; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DATABASES, FACTUAL; ELECTRONIC HEALTH RECORDS; ENZYME INDUCTION; FEMALE; FRACTURES, BONE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; TIME FACTORS;

EID: 79959565877     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2141     Document Type: Article

References (22)

1. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 1996; 71(6): 576-586.
2. Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 2007; 6(5): 465-468.
3. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767-774.
4. Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts ACG. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006; 66(9): 1318-1324.
5. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004; 45(11): 1330-1337.
6. Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. Epidemiol Rev 1997; 19(2): 244-257.
7. Leibson CL, Tosteson ANA, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002; 50(10): 1644-1650.
8. Xu Y, Hashizume T, Shuhart MC, et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha, 25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 2006; 69(1): 56-65.
9. Drug Interactions: Cytochrome P450 Drug Interaction Table. [accessed 1 April 2008].
10. Sato Y, Kondo I, Ishida S, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 2001; 57(3): 445-449.
11. Babayigit A, Dirik E, Bober E, Cakmakci H. Adverse effects of antiepileptic drugs on bone mineral density. Pediatr Neurol 2006; 35(3): 177-181.
12. Nissen-Meyer LS, Svalheim S, Tauboll E, et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia 2007; 48(10): 1850-1860.
13. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group N Engl J Med 1998; 339: 733-738.
14. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293(18): 2257-2264.
15. Gerdhem P, Ringsberg KA, Obrant KJ, Akesson K. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporos Int 2005; 16(11): 1425-1431.
16. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16(4): 393-401.
17. Lo Re V, 3rd, Haynes K, Forde KA, Localio AR, Schinnar R, Lewis JD. Validity of the health improvement network (THIN) for epidemiologic studies of Hepatitis C virus infection. Pharmacoepidemiol Drug Saf 2009; 18(9): 807-814.
18. Persson HBI, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002; 43(7): 768-772.
19. Van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HGM. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 2000; 9(5): 359-366.
20. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129(1): 125-137.
21. Christiansen C, Rodbro P. Effect of vitamin D2 on serum phenytoin. A controlled therapeutical trial. Acta Neurol Scand 1974; 50(5): 661-664.
22. Vestergaard P. Changes in bone turnover, bone mineral and fracture risk induced by drugs used to treat epilepsy. Curr Drug Saf 2008; 3: 168-172.